journalistsagainsttb

Fusing journalism and TB – telling the stories as they are

Posts Tagged ‘MDR TB

Mr Modi, I’m tempted to say,”We told you so.”

leave a comment »

India has had more than a few “I told you so!” moments at the 47th Union World Conference on Lung Health. For years now, the TB sector in India has been cautioning the government on the dangers of neglecting, or providing inadequate support, or even ignoring implementation gaps in TB control in India. The Government of India, much in the way of an impetuous, headstrong teenager, has ignored all these warnings. It has sat back complacently, happy it has a TB control programme in place and the budgets for it, regardless of how it is working on the ground. And today, on the world stage, it’s all in the open. The gaps are rearing their ugly heads for the world to see. The figures are not important; they are oft quoted. But they are also not healthy. The recently released Global TB Report 2016 strengthens the argument.

Every session at the conference be it the opening ceremony, the plenaries, or the side events, have invariably reminded us Indians in the audience that we need to do something about the very unhealthy figures for TB in India. It doesn’t  matter that arguably the biggest star in the world today, Mr Amitabh Bachchan made an impassioned plea (through a video message which was played at the inaugural) for TB control, and made us all proud for the passion he infused into it. We were reminded we had the most TB infected people in the world. It doesn’t matter we are one of the fastest growing economies and the back office of the world for the banking, insurance, healthcare and other sectors. We were reminded we have the largest number of people dying of TB in the world. It doesn’t matter we have demonstrated commitment by providing budgets for a TB control programme, provided for MDR-TB patients to get free medication and said and done all the right things. We were constantly reminded that we were contributing to the reasons for why TB was not ‘going away’ fast enough. The world cried SHAME!

Should we be bothered? I think yes. It doesn’t matter how rich we are or how productive we are as a nation. If we are contributing to death and disease and avoidable suffering in the world, and in our own country, we need to cry SHAME as well.Why, I want to ask, is our Health Minister not here to reassure the world that we are as worried about TB in India as they are? Why has he not carried a national commitment that we will pursue TB control with the same passion that we pursue the ‘Make in India’ programme or the climate change agenda or any other? To make all these possible we need a healthy population and it begins with public health.

TB is a communicable, airborne disease and we  are ‘making’ a lot of it in India. And spreading it around. I don’t care for figures; they don’t make as much sense to me as the story of Kishanlal, who died of TB needlessly. He was the main protagonist of the play staged by the Axshya Project at the Community Common.

Kishanlal was a character in the play, and yet, he should not have died. So also thousands of others who are really  dying in India simply because we have not got our act together as yet. I am deliberately avoiding quoting data because I am tired of data. Show me some faces who have overcome. Show me some faces who got help when they needed it. Show me that every person who needed help to overcome TB got it! Come on India, you can ‘Make health in India’.

I am putting this responsibility at Mr Modi’s doorstep simply because he has shown us hope by not sleeping his way through his tenure. His enthusiasm enthuses me and I am sure that his personal intervention will make a difference to the TB situation in India. Am I thinking right Mr Modi? Will you come true on your promises, broken as they are for now?

Bharathi Ghanashyam

The views expressed here are solely of the author.

A THEATRICAL PLAY PERFORMANCE BY PROJECT AXSHYA

Written by JournalistsAgainstTB

October 28, 2016 at 8:35 am

Tuberculosis control needs a complete and patient-centric solution

leave a comment »

Madhukar Pai, Prashant Yadav and Ravi Anupindi,  McGill International TB Centre, Montreal & Stephen M. Ross School of Business, University of Michigan, Ann Arbor

Whether it is mobile phone service or vacation travel, good businesses know that success depends on providing a complete and customer-centric solution. Should patients with tuberculosis not be offered a complete solution that is patient-centered? After all, millions are affected and a large market at the base-of-the-pyramid (BoP) remains unserved.

A complete and patient-centric solution will not only include care that meets the International Standards for Tuberculosis Care, but also be delivered with dignity and compassion, grounded in the reality of patients’ lives as they navigate the long pathway from symptoms to cure. Such solution-based innovation requires a systems-thinking approach that must place patients at the center of design strategies, recognize their clinical and psycho-social needs, and be cost-effective.

Pai A patient with drug-resistant tuberculosis in India [Photo credit: Bijoyeta Das (www.bijoyetadas.com)]

Because tuberculosis requires long-term treatment and involves many actors in the value chain, there needs to be an entity which, with appropriate financial support from external agencies, can orchestrate a complete solution that is affordable and locally accessible for patients.

Are tuberculosis patients in high burden countries currently getting such a patient-centric solution? Let us consider India, which accounts for quarter of all tuberculosis cases in the world. Whether patients in India seek care in the public or the private sector, they struggle to get a complete solution.

While the Revised National Tuberculosis Control Programme (RNTCP) has done well to reach scale and provide free diagnosis and treatment for patients with drug-sensitive disease in the public sector, the programme falls short in making sure that all patients get screened for drug-resistance and in ensuring adequate therapy for all patients with multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis. Of the estimated 64,000 cases of MDR-TB in 2012, only 17,373 cases were diagnosed under the RNTCP.

The diagnostic infrastructure in the public sector relies primarily on sputum smear microscopy that cannot detect drug resistance. It is only when patients fail to get better on standard treatment, or have recurrence of tuberculosis, that they get screened for MDR-TB, resulting in morbidity, continued transmission, and movement of patients from the public to the private sector.

Recognizing these problems, the RNTCP is actively scaling-up capacity to diagnose and treat MDR-TB. If adequately funded and successful, these initiatives should improve patient experience in the public sector.

But the stark reality of tuberculosis in India is that 50% of all cases are managed in the private sector, where the quality of tuberculosis care is suboptimal with inaccurate diagnosis, non-standard drug prescriptions, and limited effort to ensure treatment adherence. Also, private practitioners often do not screen for drug-resistance and empirical antibiotic abuse is rampant. All this means drug resistance can emerge or worsen, with poor outcomes. Lastly, out-of-pocket expenditure in the private sector can be catastrophic.

Are there examples of initiatives that address the above systemic problems? Operation ASHA is a non-governmental organization that extends the RNTCP model, and uses public sector diagnostics and drugs, to orchestrate a solution by establishing community-based treatment centers and ensuring adherence using local community providers and partners. It also leverages biometrics to increase efficiency and effectiveness. It relies on donors and the public sector for funding. This social enterprise model, however, does not offer a solution to patients who seek care in the private sector.

World Health Partners (WHP) is a donor-supported social marketing and social franchising model that delivers affordable reproductive and primary care (including tuberculosis) in underserved rural areas, by leveraging local entrepreneurs and informal providers, and by connecting them to the formal sector and specialists via telemedicine.

Initiative for Promoting Affordable, Quality TB tests (IPAQT), a coalition of more than 60 private laboratories, supported by non-profits like the Clinton Health Access Initiative, has increased the availability and affordability of WHO-endorsed tuberculosis tests. Although IPAQT is addressing the problem of suboptimal diagnosis, it does not cover treatment.

RNTCP recently announced “universal access to quality diagnosis and treatment for all tuberculosis patients in the community” as its goal in the new National Strategic Plan. Recognizing the need to leverage the private sector in developing a solution, the plan includes engagement of the private sector using “Public Private Interface Agencies” (PPIA) to enlist, sensitize, incentivize, and monitor diagnosis and treatment by private providers, to provide patient cost offsets such as subsidised diagnostics and free drugs to privately treated patients, and improve case notifications to the RNTCP. Ongoing PPIA pilot projects in Mumbai and Patna should inform policies for refinements and scale-up of this model.

Outside of India, Operation ASHA is now replicating its model in Cambodia. In Bangladesh, BRAC‘s tuberculosis program with shasthya shebikas has been successful in the public sector. This model is now creating linkages with private providers. In addition, they have created partnerships with garment industry owners in export processing zones that provide factory workers with better access to tuberculosis diagnosis and treatment utilizing BRAC’s infrastructure.

With donor support, Interactive Research and Development (IRD) and partners are expanding access to Xpert MTB/RIF (Cepheid Inc, CA), a WHO-endorsed test, in the private sector in Dhaka, Jakarta and Karachi, through mass verbal screening in private clinic waiting rooms, and referrals for computer-aided digital X-ray diagnosis. This model includes management of comorbid conditions such as diabetes and chronic obstructive pulmonary disease, to generate revenue for this social enterprise.

All these models are promising, but the goal of a complete, patient-centric solution is still elusive. Continued innovation in the development of scalable, sustainable and replicable business models to provide such solutions is critical.

To improve accessibility and affordability, many of the models will depend on community workers and coordinators, underscoring the need for well-designed strategies for their recruitment, training, incentivization, and performance management. Information and communications technologies will also be critical for success.

Solution-centric approaches have shown promise in several other BoP contexts, from affordable eye care to artificial limbs. By using product and process innovations, often with community champions, these models have shown that it is possible to serve the BoP market needs effectively and efficiently and with compassion and dignity. Individuals with tuberculosis deserve nothing less.

Note: This blog post is an edited version of a Comment that was published in the Lancet Global Health on 24th March 2014. The Lancet Global Health is an open access journal, and all material is published under Creative Commons licensing, with copyright retained by the authors.

The views are of the authors.

Written by JournalistsAgainstTB

March 24, 2014 at 7:56 am

%d bloggers like this: